KEY DETAILS
Eli Lilly's CEO laid out three fresh arguments for investors to keep holding the stock despite market jitters.
Hundreds of people are suing Novo Nordisk and Eli Lilly, saying they were not warned about NAION, a rare cause of sudden vision loss. Europe's regulator lists NAION as a very rare side effect of semaglutide.
As we reported on September 17, Novo Nordisk is teaming up with Anthropic to bring more AI tools into its drug discovery process.
Novo shares fell 7.7% on Sept. 21 after the company forecast only average sales growth through 2030.
A New England man claims in a lawsuit that Ozempic left him permanently blind, adding a personal case to the growing legal scrutiny.
Eli Lilly's chief executive spent part of today making the case for patience, offering investors three specific reasons to hold the stock through recent market turbulence. Across the Atlantic, Novo Nordisk shares fell 7.7 percent on Sept. 21 after its 2030 plan landed poorly. And pending lawsuits over a rare form of vision loss drew fresh coverage. For anyone following this class of drugs, today mixed corporate confidence with real caution.
Investors have watched GLP-1 stocks swing sharply this year, and Lilly's leadership used today's comments to push back on the idea that the company's momentum has stalled. The three reasons were pitched directly to shareholders who may be tempted to sell into the recent dip. Whether that reassurance holds up will depend on how the broader market treats obesity and diabetes drugmakers in the months ahead, but for now, the message from Lilly's top office was one of confidence rather than concern.
That confidence comes alongside a less comfortable development for the drug class as a whole. Hundreds of people are suing Novo Nordisk and Eli Lilly, saying they were not warned about NAION, a rare cause of sudden vision loss. These failure-to-warn suits are already pending, and they add legal risk to a category of drugs already under close public attention. Europe's medicines regulator lists NAION as a very rare side effect of semaglutide, while an American Academy of Ophthalmology review found no consistent overall rise in risk. The suits do not resolve the medical question of causation, and courts will need time to sort through the evidence. Still, for a drug class taken by millions of people, any credible legal challenge tied to vision loss is worth watching closely.
One of those manufacturers, Novo Nordisk, has also been looking toward its research pipeline. As we reported on September 17, the company announced a partnership with Anthropic on September 16 aimed at bringing more artificial intelligence tools into its drug discovery process, a move meant to speed up how new compounds are identified and tested. Pairing a major AI firm with a pharmaceutical company of Novo's size signals how central AI has become to drug development generally, not just at Novo. The partnership does not change anything about Novo's current products, but it does point to where the company intends to invest for future growth.
That forward-looking move did little to calm investors on the financial side of the business. Novo Nordisk shares fell 7.7 percent in Copenhagen on Sept. 21 after the company unveiled its plan for 2030, which promised a wave of new drugs but only average sales growth through 2030. The size of the decline shows how sensitive Novo's stock has become to any signal about its long-term strategy, especially as competition in the GLP-1 market intensifies.
Against that backdrop of legal questions raised more broadly, one lawsuit puts a specific face on the concern. A man from New England claims in a new filing that Ozempic left him permanently blind, and his case adds a personal account to the pattern of litigation now facing GLP-1 manufacturers. His claim has not been proven in court, and it represents one individual's account rather than a broader medical conclusion. But cases like his are likely to keep drawing attention to the vision loss questions raised in the broader lawsuits, particularly as more patients come forward.
For readers taking GLP-1 medications or considering them, today's news underscores two things worth keeping in mind. First, corporate confidence and stock performance do not tell the whole story of how these drugs are being scrutinized in courtrooms and in scientific reviews. Second, any concerns about vision changes or other unexpected symptoms should be discussed with a doctor rather than judged from headlines alone. The legal and business sides of this story will keep evolving, and staying informed does not require reacting to every swing in stock price or every new filing.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.